Nucleoside analogues resistance

liver411

Rev Med Interne. 2003 Dec;24(12):786-93.

[Nucleoside analogues resistance in the treatment of chronic hepatitis B
virus infection]

[Article in French]

Halfon P, Pol S, Bourliere M, Courcambeck J, Cacoub P.

Departement de virologie, laboratoire Alphabio, Marseille, France

Subject. - Chronic hepatitis B virus (HBV) infection is usually treated by
interferon alpha. However, a sustained response after stopping treatment is
only obtained in 30% of patients.Actuality. - New therapeutic nucleosid
analogs have been developped, i.e. lamivudine, famciclovir, adefovir,
entecavir, clevudine. However, as in HIV infection, clearance of the
original hepatitis B virus with emergence of distinct resistant mutants have
been observed during or after treatment with most nucleosid analogs. In this
review, the underlying mechanisms of resistance and the characterisation of
HBV mutants are described to optimize the best therapeutic
regimen.Perspectives. - Treatment of chronic HBV infection, as most of other
chronic viral infection, should be based on combination therapy with a
special search for the appearance of HBV mutant resistant.

PMID: 14656638 [PubMed - in process]